Inside the Vial: Whats Really in Compounded Semaglutide? Risks & FDA Warnings Explained

What Is Actually Inside That Compounded Semaglutide Vial?

If you have ever wondered what exactly you are injecting when you use compounded semaglutide instead of brand-name Ozempic or Wegovy, this video from Pharmacist Online digs into that question with the kind of specificity you rarely get. The presenter, a practicing pharmacist, breaks down the differences between branded semaglutide and compounded versions at a chemical and manufacturing level, while also walking through the FDA warnings that have been issued about compounded GLP-1 products.

The first thing worth understanding is that brand-name semaglutide (made by Novo Nordisk) and compounded semaglutide are not necessarily identical molecules. Novo Nordisk's semaglutide is produced using recombinant DNA technology in a biological system, which creates the full peptide with a specific fatty acid chain that gives it its long duration of action. Some compounding pharmacies produce semaglutide using chemical synthesis, which can yield the same amino acid sequence but may differ in purity, folding, and the presence of synthesis-related impurities. Other compounding pharmacies use semaglutide base or semaglutide sodium salt, which are different salt forms that may affect stability and bioavailability.

The video does a good job explaining why this matters. Even small differences in peptide purity or formulation can affect how the drug works in your body, how long it remains active, and what side effects you might experience. This is not fear-mongering. It is basic pharmaceutical science. The same active ingredient in a different formulation can behave differently, which is exactly why the FDA has extensive bioequivalence requirements for generic drugs.

The timeline of FDA warnings reflects an evolving regulatory posture that is worth understanding. Early warnings were relatively narrow, targeting specific pharmacies with documented quality failures. As the compounding market for GLP-1s grew exponentially, driven by both genuine patient need and aggressive marketing, the FDA's warnings became broader. The agency began issuing blanket statements about the risks of compounded semaglutide that did not always distinguish between different quality tiers of compounding operations. This escalation has been interpreted differently depending on perspective: as appropriate regulatory response to a growing safety concern, or as regulatory capture influenced by pharmaceutical company pressure, or some combination of both.

The FDA Warnings: Context and Specifics

The pharmacist walks through the specific FDA warnings that have been issued regarding compounded semaglutide products. These warnings have focused on several issues: products that were found to contain incorrect amounts of active ingredient (either too much or too little), products with sterility failures, products that used semaglutide sodium salt (which is not the same form used in approved products and has not undergone the same safety testing), and products from facilities with significant manufacturing deficiencies identified during FDA inspections.

What makes this presentation valuable is that it does not treat all compounded semaglutide as equally risky. The pharmacist acknowledges that some compounding operations, particularly well-run 503B outsourcing facilities, produce consistently high-quality products with thorough testing. The FDA warnings have generally targeted specific bad actors rather than condemning all compounding. But the presenter also makes the point that as a consumer, you often have limited visibility into where your specific product falls on the quality spectrum.

The FDA has also raised concerns about the marketing practices of some companies selling compounded GLP-1s. Several online platforms have been promoting compounded semaglutide directly to consumers with aggressive advertising, minimal medical oversight, and pricing structures that incentivize prescribing regardless of medical appropriateness. These operations blur the line between legitimate compounding services and direct-to-consumer drug marketing, and they have drawn justified scrutiny. The challenge is that enforcement actions against these bad actors often sweep up legitimate, well-regulated compounding pharmacies in the same regulatory net. This collateral damage is a recurring frustration for the compounding industry and for patients who rely on reputable compounded products.

One of the more eye-opening segments covers the difference between semaglutide acetate and semaglutide sodium. Some compounding pharmacies have been using semaglutide sodium salt because it is more readily available from certain chemical suppliers. However, semaglutide sodium has different properties than the semaglutide base used in Novo Nordisk's products, and there is limited clinical data on its safety and efficacy by injection. The FDA has specifically flagged this as a concern, and the video explains why in clear, accessible terms.

How to Evaluate What You Are Getting

The most actionable part of this video is the guidance on evaluating your own compounded semaglutide product. The pharmacist recommends asking for a certificate of analysis (COA) for your specific batch. A legitimate COA should include the results of potency testing (confirming the labeled amount of active ingredient), sterility testing, endotoxin testing, and pH testing at minimum. If your pharmacy cannot or will not provide this documentation, that is a red flag.

One specific technical issue the pharmacist addresses in detail is sterility testing methodology. USP 797, the standard for sterile compounding, requires growth-based sterility testing with 14-day incubation periods. Some compounding operations use rapid sterility testing methods that produce faster results but may have different sensitivity profiles. The pharmacist explains that patients should ask more than whether their product was tested for sterility, but what specific method was used and whether the results are fully documented. This level of inquiry might feel excessive, but for a product you are injecting into your body weekly, knowing the details of how it was tested is a reasonable expectation, not an unreasonable demand.

The video also recommends checking whether your compounding pharmacy uses third-party testing or relies solely on in-house testing. Third-party testing by an independent laboratory provides an additional layer of verification that in-house testing alone cannot match. Some pharmacies publish their COAs on their websites, and the presenter views that transparency favorably.

Other practical recommendations include verifying the source of the raw semaglutide ingredient (the active pharmaceutical ingredient, or API). Reputable compounding pharmacies source their API from FDA-registered facilities and can tell you the origin. Less reputable operations may use cheaper sources with less oversight. The video does not name specific suppliers, but it gives you the vocabulary and framework to have informed conversations with your pharmacy.

The pharmacist also raises an important point about formulation stability. Even when the active ingredient is properly manufactured and tested at the time of compounding, the formulation needs to remain stable over its entire shelf life. Factors like pH, temperature excursions during shipping, exposure to light, and the compatibility of the active ingredient with the specific preservatives and buffers used in the formulation all affect stability. A product that tests perfectly on day one can degrade to subtherapeutic potency by day 21 if the formulation was not properly optimized. This is why stability testing data, more than initial potency testing, is an important component of a complete certificate of analysis. Ask your pharmacy whether they have stability data supporting their beyond-use dating, and be cautious about pharmacies that cannot provide this information.

What This Video Gets Right and What It Misses

The pharmacist perspective here is genuinely valuable. Most compounding explainer videos come from either the physician side (focusing on prescribing and clinical outcomes) or the patient side (focusing on experience and affordability). Getting the pharmacist angle on what is actually in the vial, how it is made, and what quality markers to look for fills an information gap that matters for patient safety.

Where the video falls a bit short is in quantifying the actual risk. Yes, some compounded products have failed quality testing. But what percentage? How does that compare to recalls and quality failures in the branded pharmaceutical industry? Without that context, it is hard to calibrate how worried you should actually be. The video could also benefit from a more explicit discussion of cost-benefit analysis. For many patients, the choice between compounded semaglutide and no treatment at all (because they cannot afford brand-name) is the actual decision they face, and that context should inform how we talk about risk.

Questions to Ask Your Pharmacy

After watching this video, here are the questions you should be asking. What salt form of semaglutide do you use (base, acetate, or sodium)? Can you provide a certificate of analysis for my specific batch? Do you use third-party testing in addition to in-house testing? Where do you source your active pharmaceutical ingredient? Are you a 503A or 503B registered facility? What are the results of your most recent FDA or state board inspection? Any pharmacy that gets defensive about these questions rather than answering them directly is telling you something about their operation.

Who Should Watch This

This is a must-watch if you are currently using compounded semaglutide or considering it. The chemical and manufacturing details might sound technical, but the pharmacist presents them in a way that is accessible to non-professionals. It is also useful for prescribers who recommend compounded GLP-1s and want to better understand what their patients are actually receiving. If you are using brand-name Ozempic or Wegovy, this video provides useful context for understanding why the compounding debate is more nuanced than either side often presents it.